Phio Pharmaceuticals Corp. is at risk of being delisted from Nasdaq after receiving a notice regarding its stock price. On November 16, 2026, the company was informed that its common stock had closed below the $1.00 minimum bid price requirement for 30 consecutive business days. This situation is significant as it highlights the challenges faced by companies in the pharmaceutical preparations industry.

The notice from Nasdaq does not have an immediate effect on the trading of Phio's stock, but it marks a critical juncture for the company. Phio has been granted an initial period of 180 days, until May 17, 2027, to regain compliance with the minimum bid price requirement. If the stock price reaches at least $1.00 per share for a minimum of 10 consecutive business days before that date, Nasdaq will notify the company of its compliance status.

Background

Phio Pharmaceuticals Corp., incorporated in Delaware, operates in the pharmaceutical preparations sector, as classified under SIC code 2834. The company trades on the Nasdaq under the ticker symbol PHIO. Its recent filings include an 8-K report filed on November 20, 2026, which details the current situation regarding its stock price.

What the Filing Says

The filing states, "The Company intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Price Requirement." This indicates that Phio is aware of the implications of the notice and is taking steps to address the situation.

Impact

This development may affect various stakeholders, including investors, employees, and the broader market. Investors may be concerned about the company's future and its ability to maintain its listing on Nasdaq. Employees may face uncertainty regarding job security and the company's financial health. The pharmaceutical preparations industry, which includes competitors like RXi Pharmaceuticals, may also be impacted as market conditions fluctuate.

What's Next

Phio Pharmaceuticals will need to monitor its stock price closely and may explore various strategies to improve its market position. The filing does not specify any immediate next steps beyond the monitoring and evaluation process.